儿童肺动脉高血压是由于一种新型同卵性GDF2误解变异影响BMP9处理和活动
L Chomette1,2, E Hupkens3, M Romitti2
1Department of Cardiology, Hôpital Erasme, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium.
在生长差异化因子2 (GDF2) 基因的新型同卵性突变导致肺动脉高血压 (PAH) 通过防止骨形态遗传蛋白9 (BMP9) 的激活. 这一发现澄清了BMP9在PAH病变发生中的作用.
科学领域:
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
- 心血管医学 心血管医学
背景情况:
- 肺动脉高血压 (PAH) 是一种严重的血管疾病.
- 生长差异化因子2 (GDF2) 编码了骨形态遗传蛋白9 (BMP9),这是ALK1和BMPR2.2的配体.
- GDF2突变与PAH有关,但确切的机制尚不清楚.
更多相关视频
09:37Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Incomplete Dominance
